Updated Integrated Safety Analysis of Ritlecitinib up to ~ 5 Years in Patients with Alopecia Areata from the ALLEGRO Clinical Trial Program.
- DOI
- 10.1007/s40257-026-01062-x
- Published
- 2026 Sep
- Container
- American journal of clinical dermatology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s40257-026-01062-x,
title = {Updated Integrated Safety Analysis of Ritlecitinib up to \textasciitilde{} 5 Years in Patients with Alopecia Areata from the ALLEGRO Clinical Trial Program.},
author = {Senna M and Hanna S and Ueki R and Zhang X and Aguh C and Piraccini BM and Wajsbrot D and Nagy E and Sadrarhami M and Chen S and Wolk R and Tran H and Lejeune A},
year = {2026},
journal = {American journal of clinical dermatology},
doi = {10.1007/s40257-026-01062-x},
url = {https://doi.org/10.1007/s40257-026-01062-x}
}RIS
TY - JOUR TI - Updated Integrated Safety Analysis of Ritlecitinib up to ~ 5 Years in Patients with Alopecia Areata from the ALLEGRO Clinical Trial Program. AU - Senna M AU - Hanna S AU - Ueki R AU - Zhang X AU - Aguh C AU - Piraccini BM AU - Wajsbrot D AU - Nagy E AU - Sadrarhami M AU - Chen S AU - Wolk R AU - Tran H AU - Lejeune A PY - 2026 JO - American journal of clinical dermatology DO - 10.1007/s40257-026-01062-x UR - https://doi.org/10.1007/s40257-026-01062-x ER -
APA
M, S., S, H., R, U., X, Z., C, A., BM, P., D, W., E, N., M, S., S, C., R, W., H, T., & A, L. (2026). Updated Integrated Safety Analysis of Ritlecitinib up to ~ 5 Years in Patients with Alopecia Areata from the ALLEGRO Clinical Trial Program.. American journal of clinical dermatology. https://doi.org/10.1007/s40257-026-01062-x
Source records
- pubmed · retrieved 2026-09-25T19:39:08.124Z